Work

A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma

Year: 2013

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-013-0045-6

Authors: Jonathan E. Rosenberg, Richard M. Bambury, Eliezer M. Van Allen, Harry A. Drabkin, Primo N. Lara, Andrea L. Harzstark, Nikhil Wagle, Robert A. Figlin, Gregory W. Smith, Levi A. Garraway, Toni Choueiri, Fredrik Erlandsson, Damian A. Laber

Institutions: Memorial Sloan Kettering Cancer Center, Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Weill Cornell Medicine, Broad Institute, Medical University of South Carolina, University of California, Davis, University of California, San Francisco, City Of Hope National Medical Center, City of Hope, St. Francis Hospital, AstraZeneca (United Kingdom), University of Louisville

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute

Awards: G1547207268, Evaluation of a novel urothelial cancer biomarker of lethality

OpenAlex ID: W2043915025

FWCI: 15.81

Cites: 26

Cited by: 423

Related to: 10